# Intraoperative Dual-modality Imaging in Renal Cell Carcinoma

> **NCT02497599** · PHASE1 · UNKNOWN · sponsor: **Radboud University Medical Center** · enrollment: 30 (estimated)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** Indium-111-DOTA-Girentuximab-IRDye800CW
- **RADIATION:** SPECT/CT
- **PROCEDURE:** Intraoperative dual-modality imaging

## Key facts

- **NCT ID:** NCT02497599
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-06
- **Primary completion:** 2021-12
- **Final completion:** 2022-04
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02497599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02497599, "Intraoperative Dual-modality Imaging in Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02497599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*